Patents by Inventor John K Sullivan
John K Sullivan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240109955Abstract: Disclosed are antigen binding polypeptides and antigen binding polypeptide complexes (e.g., antibodies and antigen binding fragments thereof) having certain structural and/or functional features. Also disclosed are polynucleotides and vectors encoding such polypeptides and polypeptide complexes; host cells, pharmaceutical compositions and kits containing such polypeptides and polypeptide complexes; and methods of using such polypeptides and polypeptide complexes.Type: ApplicationFiled: June 30, 2023Publication date: April 4, 2024Inventors: Juan LI, Chi-Jen WEI, Ronnie R. WEI, Zhi-Yong YANG, John R. MASCOLA, Gary J. NABEL, John MISASI, Amarendra PEGU, Lingshu WANG, Tongqing ZHOU, Misook CHOE, Olamide K. OLONINIYI, Bingchun ZHAO, Yi ZHANG, Eun Sung YANG, Man CHEN, Kwanyee LEUNG, Wei SHI, Nancy J. SULLIVAN, Peter D. KWONG, Richard A. KOUP, Barney S. GRAHAM, Peng HE
-
Patent number: 8907071Abstract: Disclosed is a DNA encoding a composition of matter of the formula (X1)a—(F1)d—(X2)b—(F2)e—(X3)c??(I) and multimers thereof, in which F1 and F2 are half-life extending moieties, and d and e are each independently 0 or 1, provided that at least one of d and e is 1; X1, X2, and X3 are each independently -(L)f-P-(L)g-, and f and g are each independently 0 or 1; P is a ShK peptide analog of no more than about 80 amino acid residues in length; L is an optional linker; and a, b, and c are each independently 0 or 1, provided that at least one of a, b and c is 1. A DNA encoding the ShK peptide analog is disclosed. Also disclosed are an expression vector comprising the DNA, and a host cell comprising the expression vector.Type: GrantFiled: November 2, 2010Date of Patent: December 9, 2014Assignee: Amgen Inc.Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda, Hung Q. Nguyen, Kenneth W. Walker, Shaw-Fen Sylvia Hu, Colin V. Gegg, Stefan I. McDonough
-
Publication number: 20140147444Abstract: Selective binding agents of osteoprotegerin binding protein (OPGbp) are provided by the invention. More particularly, the invention provides for antibodies and antigen binding domains which selectively bind to OPGbp and may be used to prevent or treat conditions relating to loss of bone mass. Nucleic acid molecules encoding said antibodies and antigen binding domains, and expression vectors and host cells for the production of same are also provided.Type: ApplicationFiled: March 14, 2013Publication date: May 29, 2014Applicant: AMGEN INC.Inventors: Rajendra V. DESHPANDE, William J. BOYLE, John K. SULLIVAN, Anna Hitz
-
Patent number: 8455629Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.Type: GrantFiled: January 27, 2012Date of Patent: June 4, 2013Assignees: Amgen Inc., Medarex, Inc.Inventors: William J. Boyle, Eugene Medlock, John K. Sullivan, Robin L. Elliott, Frank Martin, Haichun Huang
-
Patent number: 8367063Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.Type: GrantFiled: May 18, 2010Date of Patent: February 5, 2013Assignees: Amgen, Inc., Medarex, Inc.Inventors: William J. Boyle, Eugene Medlock, John K. Sullivan, Robin L. Elliott, Frank Martin, Haichun Huang
-
Publication number: 20120156725Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.Type: ApplicationFiled: January 27, 2012Publication date: June 21, 2012Applicants: MEDAREX, INC., AMGEN INC.Inventors: William J. Boyle, Eugene Medlock, John K. Sullivan, Robin L. Elliott, Frank Martin, Haichun Huang
-
Publication number: 20120121591Abstract: Disclosed are compositions of matter having an amino acid sequence of SEQ ID NO:4, or a pharmaceutically acceptable salt thereof, including embodiments comprising a toxin peptide analog related to ShK, HmK, and AETX-K and pharmaceutical compositions or medicaments containing them along with a pharmaceutically acceptable carrier. Some embodiments include a half-life extending moiety. Also disclosed are a method of preventing or mitigating a relapse of a symptom of multiple sclerosis and a method of treating an autoimmune disorder using the compositions.Type: ApplicationFiled: March 19, 2010Publication date: May 17, 2012Applicant: Amgen Inc.Inventors: John K. Sullivan, Leslie P. Miranda, Colin V. Gegg, Shaw-Fen Sylvia Hu, Edward J. Belouski, Justin K. Murray, Hung Nguyen, Kenneth W. Walker, Taruna Arora, Frederick W. Jacobsen, Yue-Sheng Li, Thomas C. Boone
-
Patent number: 8043829Abstract: Disclosed is a composition of matter comprising a ShK toxin peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.Type: GrantFiled: October 25, 2007Date of Patent: October 25, 2011Assignee: Amgen Inc.Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda, Hung Q. Nguyen, Kenneth W. Walker, Shaw-Fen Sylvia Hu, Colin V. Gegg, Jr., Taruna Arora Khare, Beverly S. Adler, Francis H. Martin
-
Patent number: 7910102Abstract: Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.Type: GrantFiled: October 25, 2007Date of Patent: March 22, 2011Assignee: Amgen Inc.Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda, Hung Q. Nguyen, Kenneth W. Walker, Shaw-Fen Sylvia Hu, Colin V. Gegg, Jr., Taruna Arora Khare, Beverly S. Adler, Francis H. Martin
-
Publication number: 20110045587Abstract: Disclosed is a DNA encoding a composition of matter of the formula (X1)a—(F1)d—(X2)b—(F2)e—(X3)c??(I) and multimers thereof, in which F1 and F2 are half-life extending moieties, and d and e are each independently 0 or 1, provided that at least one of d and e is 1; X1, X2, and X3 are each independently -(L)f-P-(L)g-, and f and g are each independently 0 or 1; P is a ShK peptide analog of no more than about 80 amino acid residues in length; L is an optional linker; and a, b, and c are each independently 0 or 1, provided that at least one of a, b and c is 1. A DNA encoding the ShK peptide analog is disclosed. Also disclosed are an expression vector comprising the DNA, and a host cell comprising the expression vector.Type: ApplicationFiled: November 2, 2010Publication date: February 24, 2011Inventors: JOHN K. SULLIVAN, JOSEPH G. MCGIVERN, LESLIE P. MIRANDA, HUNG Q. NGUYEN, KENNETH W. WALKER, SHAW-FEN SYLVIA HU, COLIN V. GEGG, STEFAN I. MCDONOUGH
-
Patent number: 7833979Abstract: Disclosed is a composition of matter of the formula (X1)a—(F1)d—(X2)b—(F2)e—(X3)c??(I) and multimers thereof, in which F1 and F2 are half-life extending moieties, and d and e are each independently 0 or 1, provided that at least one of d and e is 1; X1, X2, and X3 are each independently -(L)f-P-(L)g-, and f and g are each independently 0 or 1; P is a toxin peptide of no more than about 80 amino acid residues in length, comprising at least two intrapeptide disulfide bonds; L is an optional linker; and a, b, and c are each independently 0 or 1, provided that at least one of a, b and c is 1. Linkage to the half-life extending moiety or moieties increases the in vivo half-life of the toxin peptide, which otherwise would be quickly degraded. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are a DNA encoding the inventive composition of matter, an expression vector comprising the DNA, and a host cell comprising the expression vector.Type: GrantFiled: April 17, 2006Date of Patent: November 16, 2010Assignee: Amgen Inc.Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda, Hung Q. Nguyen, Kenneth W. Walker, Shaw-Fen Sylvia Hu, Colin V. Gegg, Stefan I. McDonough
-
Patent number: 7834164Abstract: Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.Type: GrantFiled: October 25, 2007Date of Patent: November 16, 2010Assignee: Amgen Inc.Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda, Hung Q. Nguyen, Kenneth W. Walker, Shaw-Fen Sylvia Hu, Colin V. Gegg, Jr.
-
Patent number: 7825093Abstract: Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.Type: GrantFiled: October 25, 2007Date of Patent: November 2, 2010Assignee: Amgen Inc.Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda
-
Patent number: 7820623Abstract: Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.Type: GrantFiled: October 25, 2007Date of Patent: October 26, 2010Assignee: Amgen Inc.Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda, Hung Q. Nguyen, Kenneth W. Walker, Shaw-Fen Sylvia Hu, Colin V. Gegg, Jr., Taruna Arora Khare, Beverly S. Adler, Francis H. Martin
-
Patent number: 7803769Abstract: Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.Type: GrantFiled: October 25, 2007Date of Patent: September 28, 2010Assignee: Amgen Inc.Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda
-
Publication number: 20100209435Abstract: Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided.Type: ApplicationFiled: February 15, 2010Publication date: August 19, 2010Applicants: AMGEN INC., MEDAREX, INC.Inventors: William J. Boyle, Eugene Medlock, John K. Sullivan, Robin L. Elliott, Frank Martin, Haichun Huang
-
Publication number: 20090318341Abstract: Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.Type: ApplicationFiled: October 25, 2007Publication date: December 24, 2009Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda
-
Publication number: 20090305399Abstract: Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.Type: ApplicationFiled: October 25, 2007Publication date: December 10, 2009Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda, Hung Q. Nguyen, Kenneth W. Walker, Shaw-Fen Sylvia Hu, Colin V. Gegg, JR.
-
Publication number: 20090299044Abstract: Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.Type: ApplicationFiled: October 25, 2007Publication date: December 3, 2009Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda, Hung Q. Nguyen, Kenneth W. Walker, Shaw-Fen Sylvia Hu, Colin V. Gegg, JR., Taruna Arora Khare, Beverly S. Adler, Francis H. Martin
-
Publication number: 20090297520Abstract: Disclosed is a composition of matter comprising an OSK1 peptide analog, and in some embodiments, a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises the composition and a pharmaceutically acceptable carrier. Also disclosed are DNAs encoding the inventive composition of matter, an expression vector comprising the DNA, and host cells comprising the expression vector. Methods of treating an autoimmune disorder and of preventing or mitigating a relapse of a symptom of multiple sclerosis are also disclosed.Type: ApplicationFiled: October 25, 2007Publication date: December 3, 2009Inventors: John K. Sullivan, Joseph G. McGivern, Leslie P. Miranda, Hung Q. Nguyen, Kenneth W. Walker, Shaw-Fen Sylvia Hu, Colin V. Gegg, JR., Taruna Arora Khare, Beverly S. Adler, Francis H. Martin